Authors

Latest:

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Weijing Sun, MD

Latest:

Dr. Sun on the KEYNOTE-062 Design in Advanced Gastric/GEJ Cancer

Weijing Sun, MD, FACP, discusses the design of the KEYNOTE-062 trial in advanced gastric/gastroesophageal junction cancer.

Weiyun Z. Ai, MD, PhD

Latest:

Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced CTCL

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma.

Welela Tereffe, MD

Latest:

Dr. Tereffe on Treatment After Neoadjuvant Chemotherapy in Breast Cancer

Welela Tereffe, MD, associate professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the role of radiation therapy in the treatment of patients with breast cancer who previously received neoadjuvant chemotherapy.

Wells A. Messersmith, MD

Latest:

Dr. Messersmith on the Potential for Trastuzumab Deruxtecan in HER2+ CRC

Wells Messersmith, MD, discusses the potential for fam-trastuzumab deruxtecan-nxki as a treatment for patients with HER2-positive colorectal cancer.

Wells A. Messersmith, MD, FACP, University of Colorado Cancer Center

Wendy A. Woodward, MD, PhD

Latest:

New Frontier for Genomics: Radiotherapy in Early Breast Cancer

By individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.

Wendy Setiawan, PhD

Latest:

Wendy Setiawan on Pancreatic Cancer Incidence Across Ethnic Populations

Wendy Setiawan, PhD, assistant professor of Preventive Medicine, Department of Preventive Medicine, Keck School of Medicine of University of Southern California, discusses a study that examined differences in pancreatic cancer incidence across five racial/ethnic populations in a multiethnic cohort.

Whitney S. Graybill, MD, MS

Latest:

Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study

Whitney S. Graybill, MD, MS, presents data from an analysis of the phase 3 PRIMA trial that looked to identify baseline characteristics associated with long-term progression-free survival with niraparib in patients with advanced ovarian cancer.

Will Lowrance, MD, MPH

Latest:

Chronic Kidney Disease Associated With Increased Risk of Renal and Urothelial Cancers

Does renal disease increase one's risk of developing cancer?

Will Pass, DVM

Latest:

Oncologists Play Many Roles in Lung Cancer Screening Programs

The role of the oncologist is essential to the design, operation, development and associate research of lung cancer screening programs.

Willem Overwijk, PhD

Latest:

Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

William B. Donnellan, MD

Latest:

Dr. Donnellan Discusses Trials in Hematologic Malignancies

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

William C. Huang, MD

William C. Huang, MD serves as the chief of the urology service at Tisch Hospital, NYU Langone Health in new York City.

Latest:

Dr Huang on the FDA Approval of Mitomycin Intravesical Solution for Recurrent, Low-Grade, Intermediate-Risk NMIBC

William C. Huang, MD, details the FDA approval of intravesical mitomycin for recurrent, low-grade, intermediate-risk non–muscle invasive bladder cancer.

William Carroll, MD

Latest:

Making Progress in Treating Relapse in Childhood Leukemia

Having a robust armamentarium to treat childhood acute lymphoblastic leukemia (ALL) is a major triumph in oncology.

William D. Tap, MD

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center

Latest:

FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD

Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.

William D. Tap, MD, Memorial Sloan Kettering Cancer Center

William Eward, MD, DVM

Latest:

Dr. Eward on the Unmet Need for Novel Agents for TGCT and Sarcoma

William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.

William F. Symmans, MB, ChB

Latest:

Dr. Symmans on Moon Shots Program for Patients With TNBC

William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.

William F. Symmans, MD

Latest:

Dr. Symmans on the Staging System for Breast Cancer

William F. Symmans, MD, professor of Pathology, The University of Texas MD Anderson Cancer Center, discusses the staging system for patients with breast cancer.